General Information of Drug (ID: DM93MAB)

Drug Name
Dioxothiomolybdenum(VI) ion Drug Info
Synonyms DIOXOTHIOMOLYBDENUM(VI) ION; dioxo(sulfanyl)molybdenum; CHEBI:47566
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5162682
ChEBI ID
CHEBI:47566
TTD Drug ID
DM93MAB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Allopurinol DMLPAOB Gout FA25 Approved [2]
Febuxostat DMDEXQ0 Hyperuricaemia 5C55.Y Approved [3]
Fosdenopterin DMR0TYK Molybdenum cofactor deficiency 5B5K.A Approved [4]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [5]
Oxypurinol DMURH4X Heart failure BD10-BD13 Phase 2/3 [6]
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [7]
Topiroxostat DMA04DE Gout FA25 Phase 2 [8]
TMX-049 DME8PFQ Diabetic nephropathy GB61.Z Phase 2 [9]
LC-350189 DMHT3CB Gout FA25 Phase 1 [10]
Azaindole derivative 5 DMD2BL3 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Xanthine dehydrogenase/oxidase (XDH) TT7RJY8 XDH_HUMAN Inhibitor [1]

References

1 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
2 Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
3 Clinical pipeline report, company report or official report of Takeda (2009).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
5 Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
6 Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
7 Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
8 QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
9 Clinical pipeline report, company report or official report of Teijin Pharma.
10 Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
11 An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.